AIXC AIxCrypto Holdings, Inc.
HealthcareAs of 2026-05-25
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.45
P/S
0.00
EV/EBITDA
-0.02
DCF Value
$7.69
FCF Yield
-148.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-94.1%
ROA
-85.3%
ROIC
-67.7%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 null | $0.00 | $-6.1M | $— |
| Q4 null | $0.00 | $-10.6M | $— |
| FY null | $0.00 | $-17.0M | $— |
| Q3 null | $0.00 | $-2.0M | $— |
Trading Activity
Insider Trades
View AllLatest News
Company Info
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Country
US
Exchange
—
Beta
0.52
AIxCrypto Holdings, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase I clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. The company was formerly known as Qualigen Therapeutics, Inc. and changed its name to AIxCrypto Holdings, Inc. in November 2025. The company was founded in 1996 and is based in Carlsbad, California.